nodes	percent_of_prediction	percent_of_DWPC	metapath
Flutamide—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.578	0.691	CbGbCtD
Flutamide—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.258	0.309	CbGbCtD
Flutamide—Proctitis—Riluzole—amyotrophic lateral sclerosis	0.0168	0.123	CcSEcCtD
Flutamide—Methaemoglobinaemia—Riluzole—amyotrophic lateral sclerosis	0.0139	0.102	CcSEcCtD
Flutamide—Traumatic liver injury—Riluzole—amyotrophic lateral sclerosis	0.011	0.0807	CcSEcCtD
Flutamide—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00579	0.0425	CcSEcCtD
Flutamide—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.00487	0.0357	CcSEcCtD
Flutamide—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00433	0.0318	CcSEcCtD
Flutamide—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.0041	0.03	CcSEcCtD
Flutamide—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.0037	0.0272	CcSEcCtD
Flutamide—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.0037	0.0272	CcSEcCtD
Flutamide—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00342	0.0251	CcSEcCtD
Flutamide—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00321	0.0235	CcSEcCtD
Flutamide—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0232	CcSEcCtD
Flutamide—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00295	0.0216	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00268	0.0196	CcSEcCtD
Flutamide—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00237	0.0174	CcSEcCtD
Flutamide—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00235	0.0172	CcSEcCtD
Flutamide—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00223	0.0164	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—GRN—amyotrophic lateral sclerosis	0.00221	0.079	CbGpPWpGaD
Flutamide—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00218	0.016	CcSEcCtD
Flutamide—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00206	0.0151	CcSEcCtD
Flutamide—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00203	0.0149	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—SETX—amyotrophic lateral sclerosis	0.00176	0.0628	CbGpPWpGaD
Flutamide—Tension—Riluzole—amyotrophic lateral sclerosis	0.00176	0.0129	CcSEcCtD
Flutamide—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00174	0.0128	CcSEcCtD
Flutamide—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00166	0.0122	CcSEcCtD
Flutamide—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00165	0.0121	CcSEcCtD
Flutamide—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00161	0.0118	CcSEcCtD
Flutamide—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.0016	0.0118	CcSEcCtD
Flutamide—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00155	0.0113	CcSEcCtD
Flutamide—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00152	0.0111	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0111	CcSEcCtD
Flutamide—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00151	0.011	CcSEcCtD
Flutamide—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0108	CcSEcCtD
Flutamide—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00146	0.0107	CcSEcCtD
Flutamide—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00143	0.0105	CcSEcCtD
Flutamide—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00142	0.0104	CcSEcCtD
Flutamide—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00139	0.0102	CcSEcCtD
Flutamide—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00132	0.0097	CcSEcCtD
Flutamide—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.0013	0.00953	CcSEcCtD
Flutamide—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00932	CcSEcCtD
Flutamide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00924	CcSEcCtD
Flutamide—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00917	CcSEcCtD
Flutamide—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00883	CcSEcCtD
Flutamide—CYP1B1—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.00113	0.0405	CbGpPWpGaD
Flutamide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00769	CcSEcCtD
Flutamide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00758	CcSEcCtD
Flutamide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.001	0.00733	CcSEcCtD
Flutamide—AHR—Adipogenesis—RARA—amyotrophic lateral sclerosis	0.000993	0.0354	CbGpPWpGaD
Flutamide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000966	0.00709	CcSEcCtD
Flutamide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000929	0.00682	CcSEcCtD
Flutamide—Rash—Riluzole—amyotrophic lateral sclerosis	0.000921	0.00676	CcSEcCtD
Flutamide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000921	0.00675	CcSEcCtD
Flutamide—Headache—Riluzole—amyotrophic lateral sclerosis	0.000915	0.00672	CcSEcCtD
Flutamide—AR—Nuclear Receptors—RARA—amyotrophic lateral sclerosis	0.000899	0.0321	CbGpPWpGaD
Flutamide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000868	0.00637	CcSEcCtD
Flutamide—AR—Coregulation of Androgen receptor activity—HNRNPA1—amyotrophic lateral sclerosis	0.000812	0.029	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—GRN—amyotrophic lateral sclerosis	0.000749	0.0267	CbGpPWpGaD
Flutamide—AR—Nuclear Receptor transcription pathway—RARA—amyotrophic lateral sclerosis	0.000711	0.0254	CbGpPWpGaD
Flutamide—CYP1A1—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000699	0.0249	CbGpPWpGaD
Flutamide—CYP2C19—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000572	0.0204	CbGpPWpGaD
Flutamide—CYP1A1—Oxidative Stress—GSR—amyotrophic lateral sclerosis	0.000534	0.019	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000502	0.0179	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—CST3—amyotrophic lateral sclerosis	0.000468	0.0167	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—ATF1—amyotrophic lateral sclerosis	0.000449	0.016	CbGpPWpGaD
Flutamide—CYP1A2—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000445	0.0159	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000427	0.0153	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000395	0.0141	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000356	0.0127	CbGpPWpGaD
Flutamide—AR—FOXA1 transcription factor network—SOD1—amyotrophic lateral sclerosis	0.000348	0.0124	CbGpPWpGaD
Flutamide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.00032	0.0114	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—ZNF470—amyotrophic lateral sclerosis	0.000308	0.011	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.000303	0.0108	CbGpPWpGaD
Flutamide—CYP1B1—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000297	0.0106	CbGpPWpGaD
Flutamide—AHR—Adipogenesis—IGF1—amyotrophic lateral sclerosis	0.000264	0.00941	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000247	0.00882	CbGpPWpGaD
Flutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000247	0.00881	CbGpPWpGaD
Flutamide—CYP1A1—Oxidative Stress—SOD1—amyotrophic lateral sclerosis	0.000241	0.00861	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—ZNF746—amyotrophic lateral sclerosis	0.000234	0.00834	CbGpPWpGaD
Flutamide—CYP1B1—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000234	0.00833	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.00023	0.00819	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.00023	0.00819	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.00023	0.00819	CbGpPWpGaD
Flutamide—CYP1B1—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000211	0.00754	CbGpPWpGaD
Flutamide—CYP1A1—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000183	0.00653	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.00018	0.00642	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.00017	0.00606	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000165	0.00588	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000163	0.00581	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000155	0.00554	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000153	0.00545	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—ATF1—amyotrophic lateral sclerosis	0.000152	0.00542	CbGpPWpGaD
Flutamide—CYP2C19—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.00015	0.00534	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000149	0.00531	CbGpPWpGaD
Flutamide—AR—Gene Expression—ZNF470—amyotrophic lateral sclerosis	0.000148	0.0053	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000145	0.00516	CbGpPWpGaD
Flutamide—CYP1A1—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000144	0.00513	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000141	0.00502	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000138	0.00494	CbGpPWpGaD
Flutamide—CYP3A5—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000138	0.00492	CbGpPWpGaD
Flutamide—CYP1B1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000132	0.0047	CbGpPWpGaD
Flutamide—CYP1A1—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.00013	0.00464	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.00013	0.00464	CbGpPWpGaD
Flutamide—AR—Gene Expression—SMN1—amyotrophic lateral sclerosis	0.000126	0.0045	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—RARA—amyotrophic lateral sclerosis	0.000123	0.00438	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.00012	0.00428	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000119	0.00424	CbGpPWpGaD
Flutamide—CYP2C19—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000118	0.0042	CbGpPWpGaD
Flutamide—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000117	0.00416	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000115	0.00412	CbGpPWpGaD
Flutamide—AR—Gene Expression—ZNF746—amyotrophic lateral sclerosis	0.000112	0.00401	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000111	0.00396	CbGpPWpGaD
Flutamide—CYP2C19—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000107	0.0038	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000101	0.00361	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.0001	0.00358	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	9.65e-05	0.00344	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—amyotrophic lateral sclerosis	9.57e-05	0.00342	CbGpPWpGaD
Flutamide—CYP1B1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	9.46e-05	0.00338	CbGpPWpGaD
Flutamide—CYP1B1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	9.33e-05	0.00333	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	9.18e-05	0.00328	CbGpPWpGaD
Flutamide—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.17e-05	0.00327	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	9.17e-05	0.00327	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	8.92e-05	0.00318	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	8.67e-05	0.00309	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	8.52e-05	0.00304	CbGpPWpGaD
Flutamide—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	8.3e-05	0.00296	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	8.2e-05	0.00293	CbGpPWpGaD
Flutamide—CYP1A1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	8.11e-05	0.00289	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	8.01e-05	0.00286	CbGpPWpGaD
Flutamide—AR—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	7.8e-05	0.00278	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	7.5e-05	0.00268	CbGpPWpGaD
Flutamide—AR—Gene Expression—FUS—amyotrophic lateral sclerosis	7.25e-05	0.00259	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—TPK1—amyotrophic lateral sclerosis	7.25e-05	0.00259	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—VAPB—amyotrophic lateral sclerosis	7.25e-05	0.00259	CbGpPWpGaD
Flutamide—AR—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	7.02e-05	0.00251	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	6.97e-05	0.00249	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	6.83e-05	0.00244	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	6.76e-05	0.00241	CbGpPWpGaD
Flutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	6.63e-05	0.00237	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—VAPA—amyotrophic lateral sclerosis	6.63e-05	0.00237	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	6.56e-05	0.00234	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	6.56e-05	0.00234	CbGpPWpGaD
Flutamide—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	6.41e-05	0.00229	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	6.39e-05	0.00228	CbGpPWpGaD
Flutamide—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	6.35e-05	0.00227	CbGpPWpGaD
Flutamide—CYP3A5—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.17e-05	0.0022	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.16e-05	0.0022	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	6.09e-05	0.00217	CbGpPWpGaD
Flutamide—CYP3A5—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.08e-05	0.00217	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	5.94e-05	0.00212	CbGpPWpGaD
Flutamide—AR—Gene Expression—RARA—amyotrophic lateral sclerosis	5.91e-05	0.00211	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	5.84e-05	0.00209	CbGpPWpGaD
Flutamide—CYP1A1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.82e-05	0.00208	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—FIG4—amyotrophic lateral sclerosis	5.79e-05	0.00207	CbGpPWpGaD
Flutamide—CYP1A1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.74e-05	0.00205	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	5.53e-05	0.00197	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	5.49e-05	0.00196	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	5.44e-05	0.00194	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	5.43e-05	0.00194	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—DAO—amyotrophic lateral sclerosis	5.24e-05	0.00187	CbGpPWpGaD
Flutamide—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	5.17e-05	0.00184	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	5.17e-05	0.00184	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	5.11e-05	0.00182	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	5.05e-05	0.0018	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	5.04e-05	0.0018	CbGpPWpGaD
Flutamide—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.77e-05	0.0017	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	4.72e-05	0.00169	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	4.72e-05	0.00169	CbGpPWpGaD
Flutamide—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	4.7e-05	0.00168	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	4.49e-05	0.0016	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—TPK1—amyotrophic lateral sclerosis	4.46e-05	0.00159	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—VAPB—amyotrophic lateral sclerosis	4.46e-05	0.00159	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	4.35e-05	0.00155	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	4.32e-05	0.00154	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	4.28e-05	0.00153	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.16e-05	0.00149	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—VAPA—amyotrophic lateral sclerosis	4.08e-05	0.00146	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.02e-05	0.00143	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PLB1—amyotrophic lateral sclerosis	3.97e-05	0.00142	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.91e-05	0.00139	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.8e-05	0.00135	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	3.78e-05	0.00135	CbGpPWpGaD
Flutamide—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.71e-05	0.00133	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—GSR—amyotrophic lateral sclerosis	3.66e-05	0.00131	CbGpPWpGaD
Flutamide—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.66e-05	0.00131	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	3.65e-05	0.0013	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	3.65e-05	0.0013	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.57e-05	0.00127	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	3.5e-05	0.00125	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	3.42e-05	0.00122	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	3.41e-05	0.00122	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	3.34e-05	0.00119	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.34e-05	0.00119	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.24e-05	0.00116	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—DAO—amyotrophic lateral sclerosis	3.23e-05	0.00115	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.11e-05	0.00111	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.01e-05	0.00107	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	2.92e-05	0.00104	CbGpPWpGaD
Flutamide—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.87e-05	0.00102	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.85e-05	0.00102	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.85e-05	0.00102	CbGpPWpGaD
Flutamide—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	2.83e-05	0.00101	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.75e-05	0.00098	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	2.65e-05	0.000947	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	2.64e-05	0.000942	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.6e-05	0.000929	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	2.59e-05	0.000924	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.45e-05	0.000873	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.42e-05	0.000864	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	2.39e-05	0.000853	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.28e-05	0.000812	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	2.26e-05	0.000805	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.2e-05	0.000784	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.2e-05	0.000784	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.06e-05	0.000734	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.06e-05	0.000734	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	2.01e-05	0.000717	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	2e-05	0.000714	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	1.96e-05	0.0007	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.88e-05	0.000671	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.87e-05	0.000666	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.85e-05	0.000661	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	1.85e-05	0.000659	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	1.76e-05	0.000627	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.69e-05	0.000604	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.68e-05	0.0006	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.62e-05	0.000577	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.59e-05	0.000567	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.56e-05	0.000556	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	1.52e-05	0.000541	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.49e-05	0.00053	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.44e-05	0.000514	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.38e-05	0.000494	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.31e-05	0.000468	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—APOE—amyotrophic lateral sclerosis	1.22e-05	0.000436	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.2e-05	0.000429	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.18e-05	0.000422	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.16e-05	0.000414	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.11e-05	0.000396	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.08e-05	0.000385	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.05e-05	0.000376	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.96e-06	0.000355	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.69e-06	0.000346	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	9.48e-06	0.000338	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.15e-06	0.000327	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	9.12e-06	0.000325	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.38e-06	0.000299	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	8.15e-06	0.000291	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	7.97e-06	0.000284	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	7.53e-06	0.000269	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.49e-06	0.000267	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	7.39e-06	0.000264	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.35e-06	0.000227	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	6.16e-06	0.00022	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.84e-06	0.000208	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.46e-06	0.000195	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.16e-06	0.000184	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.9e-06	0.000175	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	4.8e-06	0.000171	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.5e-06	0.000161	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.22e-06	0.000151	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	3.71e-06	0.000132	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.29e-06	0.000117	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.54e-06	9.06e-05	CbGpPWpGaD
